- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
Case Reports in Pediatrics
Volume 2012 (2012), Article ID 624168, 5 pages
Mycophenolate Mofetil-Related Enterocolitis and Weight Loss: A Pediatric Case Series
1Division of Gastroenterology Hepatology and Nutrition, Cincinnati Children’s, 3333 Burnet Avenue MLC 2010, Cincinnati, OH 45229-3039, USA
2Division of Gastroenterology, University of Southern California, 4650 Sunset Boulevard, MS #126, Los Angeles, CA 90027, USA
3Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Vanderbilt University School of Medicine, 2200 Children's Way, 11th Floor, Doctors' Office Tower, Nashville, TN 37232-2576, USA
4Seacoast Pathology, Aurora Diagnostics, 1 Hampton Road, Suite 208, Exeter, NH 03833-4849, USA
5Division of Gastroenterology, Oschner Children’s Health Center, 1315 Jefferson Highway, New Orleans, LA 70121, USA
6Division of Pediatric Gastroenterology and Nutrition Sciences, University of Alabama at Birmingham, 1600 7th Avenue. S., Lowder Blgd., Ste. 618, Birmingham, AL 35233, USA
7Department of Nephrology, University of Minnesota, Pediatric Specialty Care Discovery Clinic, 2512 Building, 2512 S. 7th Street, Minneapolis, MN 55454, USA
8Division of Pediatric Nephrology, Vanderbilt University School of Medicine, 2200 Children's Way, 11th Floor, Doctors' Office Tower, Nashville, TN 37232, USA
9Department of Pathology, University of Arizona, 1501 N. Campbell Avenue, P.O. Box 245108, Tucson, AZ 85724-5108, USA
Received 10 August 2012; Accepted 6 September 2012
Academic Editors: E. Czkwianianc, A. W. Kamps, and D. I. Zafeiriou
Copyright © 2012 Dana M. H. Dykes et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- L. Quéméneur, M. Flacher, L. M. Gerland, M. Ffrench, J. P. Revillard, and N. Bonnefoy-Berard, “Mycophenolic acid inhibits IL-2-dependent T cell proliferation, but not IL-2-dependent survival and sensitization to apoptosis,” Journal of Immunology, vol. 169, no. 5, pp. 2747–2755, 2002.
- P. F. Halloran, “Molecular mechanisms of new immunosuppressants,” Clinical Transplantation, vol. 10, no. 1, pp. 118–123, 1996.
- W. D. Simmons, S. C. Rayhill, and H. W. Sollinger, “Preliminary risk-benefit assessment of mycophenolate mofetil in transplant rejection,” Drug Safety, vol. 17, no. 2, pp. 75–92, 1997.
- J. C. Papadimitriou, C. B. Cangro, A. Lustberg et al., “Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern,” International Journal of Surgical Pathology, vol. 11, no. 4, pp. 295–302, 2003.
- U. P. Phatak, P. Seo-Mayer, D. Jain, M. Selbst, S. Husain, and D. S. Pashankar, “Mycophenolate mofetil-induced colitis in children,” Journal of Clinical Gastroenterology, vol. 43, no. 10, pp. 967–969, 2009.
- L. M. Sollid and B. A. Lie, “Celiac disease genetics: current concepts and practical applications,” Clinical Gastroenterology and Hepatology, vol. 3, no. 9, pp. 843–851, 2005.
- B. D. Maes, I. Dalle, K. Geboes et al., “Erosive enterocolitis in mycophenolate mofetil-treated renal-transplant recipients with persistent afebrile diarrhea,” Transplantation, vol. 75, no. 5, pp. 665–672, 2003.
- S. Al-shamma, M. Fox, F. Campbell, P. Collins, and M. Lombard, “Diarrhoea and weight loss in an immunosuppressed patient,” Gut, vol. 59, no. 9, pp. 1225–1302, 2010.
- E. C. Gorospe, “Chronic diarrhoea from mycophenolate mofetil-induced colitis,” BMJ Case Reports. In press.
- M. M. Skelly, R. F. A. Logan, D. Jenkins, Y. R. Mahida, and C. J. Hawkey, “Toxicity of mycophenolate mofetil in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 8, no. 2, pp. 93–97, 2002.
- D. Ducloux, Y. Ottignon, S. Semhoun-Ducloux et al., “Mycophenolate mofetil-induced villous atrophy,” Transplantation, vol. 66, no. 8, pp. 1115–1116, 1998.
- N. Kamar, P. Faure, E. Dupuis et al., “Villous atrophy induced by mycophenolate mofetil in renal-transplant patients,” Transplant International, vol. 17, no. 8, pp. 463–467, 2004.
- M. K. Selbst, W. A. Ahrens, M. E. Robert, A. Friedman, D. D. Proctor, and D. Jain, “Spectrum of histologic changes in colonic biopsies in patients treated with mycophenolate mofetil,” Modern Pathology, vol. 22, no. 6, pp. 737–743, 2009.
- W. Arns, S. Breuer, S. Choudhury et al., “Enteric-coated mycophenolate sodium delivers bioequivalent MPA exposure compared with mycophenolate mofetil,” Clinical Transplantation, vol. 19, no. 2, pp. 199–206, 2005.
- A. T. Wan Song, E. Abdala, P. Rodrigues Bonazzi, T. Bacchella, and M. C. C. Machado, “Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients?–a mini-review,” Brazilian Journal of Infectious Diseases, vol. 10, no. 2, pp. 132–138, 2006.